{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T16:16:12Z","timestamp":1778084172632,"version":"3.51.4"},"reference-count":41,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Nirmatrelvir-ritonavir is an oral antiviral recommended for treating high-risk individuals with COVID-19 in the community. However, there remains uncertainty over its cost-effectiveness in largely vaccinated populations and subgroups defined by age and clinical risk.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To compare the cost-effectiveness of nirmatrelvir-ritonavir vs usual care based on the UK Platform Adaptative Trial of Novel Antivirals for Early Treatment of COVID-19 in the Community (PANORAMIC) trial.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This economic evaluation was a within-trial cost-utility analysis conducted using data from the PANORAMIC trial and linked routine health care data from December 8, 2021, to September 30, 2024, adopting a UK National Health Service (NHS) and personal social services perspective over 6 months. Eligible participants were community-dwelling adults aged 50 years and older or ages 18 to 49 years with comorbidities. Data were analyzed from April 20, 2022, to September 30, 2024, for the nirmatrelvir-ritonavir group and December 8, 2021, to September 30, 2026, for usual care.<\/jats:p>\n <\/jats:sec>\n \n Intervention<\/jats:title>\n Oral nirmatrelvir-ritonavir.<\/jats:p>\n <\/jats:sec>\n \n Main Outcome and Measures<\/jats:title>\n Cost, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratio (ICER) of nirmatrelvir-ritonavir vs usual care.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n There were 1736 participants randomized to receive nirmatrelvir-ritonavir plus usual care (mean [SE] age, 54.7 [0.29] years), and 1768 to usual care alone (mean [SE] age, 54.8 [0.28] years); 2405 in the total cohort were female (69.2%]), and 3455 (98.6%) were vaccinated. Nirmatrelvir-ritonavir was cost-effective, on average, with lower total costs (\u00a3124; 95% CI, \u2013\u00a31207 to \u00a31455) and higher QALYs (0.0110; 95% CI, 0.0062-0.0170) over 6 months compared with usual care (ICER, \u00a310\u202f897 per QALY). Nirmatrelvir-ritonavir had a 0.65 probability of being cost-effective at a \u00a320\u202f000 per QALY cost-effectiveness threshold, indicating decision uncertainty. The intervention remained cost-effective in most sensitivity analyses and prespecified subgroups, although several subgroup analyses were based on small sample sizes and should be interpreted as exploratory.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this economic evaluation of nirmatrelvir-ritonavir for COVID-19, cost-effectiveness varied by age, comorbidity, and vaccination status. Subgroup findings should be interpreted with caution, but targeted prescribing for at-risk adults aged 18 to 64 years, those aged 65 to 69 years, and adults aged 75 years and above, particularly those with comorbidities and not recently vaccinated, was likely to provide the greatest health system value; cost-effectiveness was not observed in low-risk adults aged 50 to 64 years, those aged 70 to 74 years, or in unvaccinated or recently vaccinated individuals.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.12381","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T15:30:37Z","timestamp":1778081437000},"page":"e2612381","source":"Crossref","is-referenced-by-count":0,"title":["Economic Evaluation of Oral Nirmatrelvir-Ritonavir for COVID-19 in Higher Risk Outpatients"],"prefix":"10.1001","volume":"9","author":[{"given":"May Ee","family":"Png","sequence":"first","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Harris","sequence":"additional","affiliation":[{"name":"Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ly-Mee","family":"Yu","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Little","sequence":"additional","affiliation":[{"name":"Primary Care Research Centre, University of Southampton, Southampton, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. D. Richard","family":"Hobbs","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom"},{"name":"Oxford Institute of Digital Health, University of Oxford, Oxford, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher C.","family":"Butler","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stavros","family":"Petrou","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"PANORAMIC Trial Collaborative Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oghenekome A","family":"Gbinigie","sequence":"additional","affiliation":[{"name":"for the PANORAMIC Trial Collaborative Group"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Najib M","family":"Rahman","sequence":"additional","affiliation":[{"name":"for the PANORAMIC Trial Collaborative Group"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gail","family":"Hayward","sequence":"additional","affiliation":[{"name":"for the PANORAMIC Trial Collaborative Group"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duncan B","family":"Richards","sequence":"additional","affiliation":[{"name":"for the PANORAMIC Trial Collaborative Group"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jienchi","family":"Dorward","sequence":"additional","affiliation":[{"name":"for the PANORAMIC Trial Collaborative Group"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M","family":"Lowe","sequence":"additional","affiliation":[{"name":"for the PANORAMIC Trial Collaborative Group"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph F","family":"Standing","sequence":"additional","affiliation":[{"name":"for the PANORAMIC Trial Collaborative Group"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Breuer","sequence":"additional","affiliation":[{"name":"for the PANORAMIC Trial Collaborative Group"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saye","family":"Khoo","sequence":"additional","affiliation":[{"name":"for the PANORAMIC Trial Collaborative Group"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerenza","family":"Hood","sequence":"additional","affiliation":[{"name":"for the PANORAMIC Trial Collaborative Group"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan S","family":"Nguyen-Van-Tam","sequence":"additional","affiliation":[{"name":"for the PANORAMIC Trial Collaborative Group"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahendra G","family":"Patel","sequence":"additional","affiliation":[{"name":"for the PANORAMIC Trial Collaborative Group"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin R","family":"Saville","sequence":"additional","affiliation":[{"name":"for the PANORAMIC Trial Collaborative Group"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joe","family":"Marion","sequence":"additional","affiliation":[{"name":"for the PANORAMIC Trial Collaborative Group"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick","family":"Francis","sequence":"additional","affiliation":[{"name":"for the PANORAMIC Trial Collaborative Group"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas P B","family":"Thomas","sequence":"additional","affiliation":[{"name":"for the PANORAMIC Trial Collaborative Group"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Evans","sequence":"additional","affiliation":[{"name":"for the PANORAMIC Trial Collaborative Group"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Dobson","sequence":"additional","affiliation":[{"name":"for the PANORAMIC Trial Collaborative Group"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Holmes","sequence":"additional","affiliation":[{"name":"for the PANORAMIC Trial Collaborative Group"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Harris","sequence":"additional","affiliation":[{"name":"for the PANORAMIC Trial Collaborative Group"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Lown","sequence":"additional","affiliation":[{"name":"for the PANORAMIC Trial Collaborative Group"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"van Hecke","sequence":"additional","affiliation":[{"name":"for the PANORAMIC Trial Collaborative Group"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle A","family":"Detry","sequence":"additional","affiliation":[{"name":"for the PANORAMIC Trial Collaborative Group"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina T","family":"Saunders","sequence":"additional","affiliation":[{"name":"for the PANORAMIC Trial Collaborative Group"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Fitzgerald","sequence":"additional","affiliation":[{"name":"for the PANORAMIC Trial Collaborative Group"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas S","family":"Berry","sequence":"additional","affiliation":[{"name":"for the PANORAMIC Trial Collaborative Group"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sam","family":"Mort","sequence":"additional","affiliation":[{"name":"for the PANORAMIC Trial Collaborative Group"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhautesh D","family":"Jani","sequence":"additional","affiliation":[{"name":"for the PANORAMIC Trial Collaborative Group"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nigel D","family":"Hart","sequence":"additional","affiliation":[{"name":"for the PANORAMIC Trial Collaborative Group"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haroon","family":"Ahmed","sequence":"additional","affiliation":[{"name":"for the PANORAMIC Trial Collaborative Group"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Butler","sequence":"additional","affiliation":[{"name":"for the PANORAMIC Trial Collaborative Group"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micheal","family":"McKenna","sequence":"additional","affiliation":[{"name":"for the PANORAMIC Trial Collaborative Group"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucy","family":"Cureton","sequence":"additional","affiliation":[{"name":"for the PANORAMIC Trial Collaborative Group"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meena","family":"Patil","sequence":"additional","affiliation":[{"name":"for the PANORAMIC Trial Collaborative Group"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monique","family":"Andersson","sequence":"additional","affiliation":[{"name":"for the PANORAMIC Trial Collaborative Group"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clare","family":"Bateman","sequence":"additional","affiliation":[{"name":"for the PANORAMIC Trial Collaborative Group"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer C","family":"Davies","sequence":"additional","affiliation":[{"name":"for the PANORAMIC Trial Collaborative Group"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Ustianowski","sequence":"additional","affiliation":[{"name":"for the PANORAMIC Trial Collaborative Group"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew Carson","family":"Stevens","sequence":"additional","affiliation":[{"name":"for the PANORAMIC Trial Collaborative Group"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"issue":"15","key":"zoi260376r2","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19.","volume":"386","author":"Hammond","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi260376r3","doi-asserted-by":"publisher","first-page":"77","DOI":"10.7326\/M22-2141","article-title":"Nirmatrelvir plus ritonavir for early COVID-19 in a large US health system: a population-based cohort study.","volume":"176","author":"Dryden-Peterson","year":"2023","journal-title":"Ann Intern Med"},{"issue":"6","key":"zoi260376r4","doi-asserted-by":"publisher","first-page":"E220","DOI":"10.1503\/cmaj.221608","article-title":"Population-based evaluation of the effectiveness of nirmatrelvir-ritonavir for reducing hospital admissions and mortality from COVID-19.","volume":"195","author":"Schwartz","year":"2023","journal-title":"CMAJ"},{"issue":"12","key":"zoi260376r6","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac637","article-title":"Population-level strategies for nirmatrelvir\/ritonavir prescribing\u2014a cost-effectiveness analysis.","volume":"9","author":"Savinkina","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"8","key":"zoi260376r7","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.jiac.2024.02.001","article-title":"Cost-effectiveness of nirmatrelvir\/ritonavir for high-risk adult outpatients with COVID-19 in Japan.","volume":"30","author":"Mizuno","year":"2024","journal-title":"J Infect Chemother"},{"issue":"1","key":"zoi260376r8","doi-asserted-by":"publisher","first-page":"75","DOI":"10.36469\/jheor.2025.129067","article-title":"Cost-effectiveness analysis of nirmatrelvir\/ritonavir compared with molnupiravir in patients at high risk for progression to severe COVID-19 in Japan.","volume":"12","author":"Yuasa","year":"2025","journal-title":"J Health Econ Outcomes Res"},{"issue":"3","key":"zoi260376r9","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.70288","article-title":"Cost-effectiveness of nirmatrelvir\/ritonavir in COVID-19 patients at high-risk for progression in Spain.","volume":"97","author":"Azanza","year":"2025","journal-title":"J Med Virol"},{"issue":"2","key":"zoi260376r10","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jval.2023.11.003","article-title":"Cost-effectiveness of oral nirmatrelvir\/ritonavir in patients at high risk for progression to severe COVID-19 in the United States.","volume":"27","author":"Carlson","year":"2024","journal-title":"Value Health"},{"issue":"4","key":"zoi260376r11","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf187","article-title":"Cost-effectiveness analysis of nirmatrelvir\/ritonavir for COVID-19 among individuals at high risk: a modeling study.","volume":"12","author":"Birnie","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"zoi260376r12","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ejim.2023.09.025","article-title":"Cost-effectiveness analysis of ritonavir boosted nirmatrelvir for adult outpatients with mild to moderate COVID-19 in a European health system.","volume":"118","author":"Wikman-Jorgensen","year":"2023","journal-title":"Eur J Intern Med"},{"key":"zoi260376r13","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2024.1432821","article-title":"Real-world cost-effectiveness of nirmatrelvir-ritonavir as treatment for SARS-CoV-2 infection in the Belgian setting with omicron variant.","volume":"12","author":"Marbaix","year":"2025","journal-title":"Front Public Health"},{"issue":"1","key":"zoi260376r14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12962-025-00604-0","article-title":"Cost-effectiveness of nirmatrelvir\/ritonavir in COVID-19 patient groups at high risk for progression to severe COVID-19 in the Netherlands.","volume":"23","author":"Arteaga Duarte","year":"2025","journal-title":"Cost Eff Resour Alloc"},{"key":"zoi260376r15","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.vhri.2023.09.005","article-title":"Cost-utility model of nirmatrelvir\/ritonavir in Brazil: analysis of a vaccinated population.","volume":"40","author":"Fernandes","year":"2024","journal-title":"Value Health Reg Issues"},{"issue":"1","key":"zoi260376r16","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1080\/13696998.2024.2444836","article-title":"Cost-effectiveness of outpatient COVID-19 antiviral treatment with nirmatrelvir\/ritonavir versus usual care in Swedish patients with various risk factors.","volume":"28","author":"Nilsson","year":"2025","journal-title":"J Med Econ"},{"key":"zoi260376r17","doi-asserted-by":"publisher","DOI":"10.4178\/epih.e2022034","article-title":"Model-based cost-effectiveness analysis of oral antivirals against SARS-CoV-2 in Korea.","volume":"44","author":"Jo","year":"2022","journal-title":"Epidemiol Health"},{"key":"zoi260376r18","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1174879","article-title":"Cost-effectiveness of Paxlovid in reducing severe COVID-19 and mortality in China.","volume":"11","author":"Zhang","year":"2023","journal-title":"Front Public Health"},{"key":"zoi260376r19","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2022.100602","article-title":"Association of molnupiravir and nirmatrelvir-ritonavir with preventable mortality, hospital admissions and related avoidable healthcare system cost among high-risk patients with mild to moderate COVID-19.","volume":"30","author":"Wai","year":"2023","journal-title":"Lancet Reg Health West Pac"},{"issue":"2","key":"zoi260376r20","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40801-024-00427-0","article-title":"Economic evaluation of nirmatrelvir\/ritonavir among adults against hospitalization during the Omicron dominated period in Malaysia: a real-world evidence perspective.","volume":"11","author":"Low","year":"2024","journal-title":"Drugs Real World Outcomes"},{"issue":"10373","key":"zoi260376r22","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0140-6736(22)02597-1","article-title":"Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial.","volume":"401","author":"Butler","year":"2023","journal-title":"Lancet"},{"issue":"745","key":"zoi260376r23","doi-asserted-by":"publisher","first-page":"e570","DOI":"10.3399\/BJGP.2023.0444","article-title":"Cost-utility analysis of molnupiravir for high-risk, community-based adults with COVID-19: an economic evaluation of the PANORAMIC trial.","volume":"74","author":"Png","year":"2024","journal-title":"Br J Gen Pract"},{"issue":"10","key":"zoi260376r31","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L).","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"issue":"11","key":"zoi260376r34","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1007\/s40273-023-01301-7","article-title":"Conducting trial-based economic evaluations using R: a tutorial.","volume":"41","author":"Ben","year":"2023","journal-title":"Pharmacoeconomics"},{"issue":"12","key":"zoi260376r35","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1007\/s40273-014-0193-3","article-title":"A guide to handling missing data in cost-effectiveness analysis conducted within randomised controlled trials.","volume":"32","author":"Faria","year":"2014","journal-title":"Pharmacoeconomics"},{"issue":"14","key":"zoi260376r37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta19140","article-title":"Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold.","volume":"19","author":"Claxton","year":"2015","journal-title":"Health Technol Assess"},{"issue":"10","key":"zoi260376r38","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1302\/0301-620X.105B10.BJJ-2023-0633","article-title":"Cost-utility analysis of dual-antibiotic cement versus single-antibiotic cement for the treatment of displaced intracapsular hip fractures in older adults.","volume":"105-B","author":"Png","year":"2023","journal-title":"Bone Joint J"},{"issue":"8","key":"zoi260376r39","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-069176","article-title":"Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community (PANORAMIC): protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe disease.","volume":"13","author":"Gbinigie","year":"2023","journal-title":"BMJ Open"},{"issue":"4","key":"zoi260376r40","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1038\/s41591-022-01699-1","article-title":"Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England.","volume":"28","author":"Andrews","year":"2022","journal-title":"Nat Med"},{"issue":"7","key":"zoi260376r41","doi-asserted-by":"publisher","first-page":"255","DOI":"10.15585\/mmwr.mm7107e2","article-title":"Waning 2-dose and 3-dose effectiveness of mRNA vaccines against COVID-19\u2013associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and Omicron variant predominance\u2014VISION Network, 10 states, August 2021-January 2022.","volume":"71","author":"Ferdinands","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"zoi260376r33","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198529446.001.0001","volume-title":"Methods for the Economic Evaluation of Health Care Programmes (Third Edition)","author":"Drummond","year":"2005"},{"key":"zoi260376r1","unstructured":"US Food & Drug Administration. FDA approves first oral antiviral for treatment of COVID-19 in adults. May 25, 2023. Accessed July 2, 2025. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-oral-antiviral-treatment-covid-19-adults"},{"key":"zoi260376r5","unstructured":"World Health Organization. WHO recommends highly successful COVID-19 therapy and calls for wide geographical distribution and transparency from originator. April 22, 2022. Accessed July 2, 2025. https:\/\/www.who.int\/news\/item\/22-04-2022-who-recommends-highly-successful-covid-19-therapy-and-calls-for-wide-geographical-distribution-and-transparency-from-originator"},{"key":"zoi260376r21","unstructured":"National Institute for Health and Care Excellence. NICE health technology evaluations: the manual. January 31, 2022. Accessed February 23, 2022. https:\/\/www.nice.org.uk\/process\/pmg36\/chapter\/introduction-to-health-technology-evaluation"},{"key":"zoi260376r24","doi-asserted-by":"crossref","unstructured":"Honaker? J, King? G, Blackwell? M. Amelia II: a program for missing data.? J Stat Software. 2011;45(7):1-47. doi:10.18637\/jss.v045.i07","DOI":"10.18637\/jss.v045.i07"},{"key":"zoi260376r25","unstructured":"Jones? K, Weatherly? H, Birch? S, . Unit costs of health and social care 2024 manual. University of Kent Personal Social Services Research Unit and University of York Centre for Health Economics technical report. Published online April 8, 2025. Accessed September 29, 2025. https:\/\/kar.kent.ac.uk\/109563\/"},{"key":"zoi260376r26","unstructured":"National Health Service. National cost collection for the NHS. 2024. Accessed June 20, 2025. https:\/\/www.england.nhs.uk\/costing-in-the-nhs\/national-cost-collection\/"},{"key":"zoi260376r27","unstructured":"Business Services Authority. Prescription cost analysis (PCA) data. 2021. Accessed April 23, 2021. https:\/\/www.nhsbsa.nhs.uk\/prescription-data\/dispensing-data\/prescription-cost-analysis-pca-data"},{"key":"zoi260376r28","unstructured":"British National Formulary. Nirmatrelvir with ritonavir: medicinal forms. 2025. Accessed July 2, 2025. https:\/\/bnf.nice.org.uk\/drugs\/nirmatrelvir-with-ritonavir\/medicinal-forms\/"},{"key":"zoi260376r29","unstructured":"Office for National Statistics. Employee earnings in the UK: 2024. Published online October 29, 2024. Accessed May 14, 2025. https:\/\/www.ons.gov.uk\/employmentandlabourmarket\/peopleinwork\/earningsandworkinghours\/bulletins\/annualsurveyofhoursandearnings\/2024"},{"key":"zoi260376r30","unstructured":"Office for National Statistics. Gender pay gap in the UK: 2024. Published online October 29, 2024. Accessed May 14, 2025. https:\/\/www.ons.gov.uk\/employmentandlabourmarket\/peopleinwork\/earningsandworkinghours\/bulletins\/genderpaygapintheuk\/2024"},{"key":"zoi260376r32","doi-asserted-by":"crossref","unstructured":"Hernandez Alava? M, Pudney? S, Wailoo? A. Estimating the relationship between EQ-5D-5L and EQ-5D-3L: results from an English population study. 2020. Accessed February 23, 2022. https:\/\/sheffield.ac.uk\/nice-dsu\/methods-development\/mapping-eq-5d-5l-3l","DOI":"10.1007\/s40273-022-01218-7"},{"key":"zoi260376r36","unstructured":"National Institute for Health and Care Excellence. Judging whether public health interventions offer value for money. September 1, 2013. Accessed July 1, 2018. https:\/\/www.nice.org.uk\/advice\/lgb10\/chapter\/judging-the-cost-effectiveness-of-public-health-activities"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2848671\/png_2026_oi_260376_1777494522.89166.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T15:30:58Z","timestamp":1778081458000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2848671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.12381","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]}}}